Ablynx Announces Warrant Exercise

Regulated Information

(firmenpresse) - GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the Company in exchange for EUR 884,476.40 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 48,802,115 shares outstanding.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.

More information can be found on .

press release in pdf format:



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2330
e:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 23.07.2013 - 16:32 Uhr
Sprache: Deutsch
News-ID 281023
Anzahl Zeichen: 0

contact information:
Town:

GHENT, BELGIUM

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 455 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ablynx Announces Warrant Exercise"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Starts Additional Phase I Studies With Anti-RSV Nanobody ALX-0171 ...

GHENT, BELGIUM -- (Marketwired) -- 07/04/13 -- (EURONEXT BRUSSELS: ABLX) today announced that it has initiated two additional Phase I studies with its anti-RSV Nanobody®, ALX-0171, with the goal of commencing paediatric development during the secon ...

Alle Meldungen von Ablynx